Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia

Abstract

OBJECTIVE -Lactic acidosis has been associated with use of metformin. Hypoglycemia is a major concern using sulfonylureas. The aim of this study was to compare the risk of lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral antidiabetes drugs. RESEARCH DESIGN AND METHODS-This study is a nested case-control analysis using the U.K.-based General Practice Research Database to identify patients with type 2 diabetes who used oral antidiabetes drugs. Within the study population, all incident cases of lactic acidosis and hypoglycemia were identified, and hypoglycemia case subjects were matched to up to four control patients based on age, sex, practice, and calendar time.RESULTS -Among the study population of 50,048 type 2 diabetic subjects, six cases of lactic acidosis during current use of oral antidiabetes drugs were identified, yielding a crude incidence rate of 3.3 cases per 100,000 person-years among metformin users and 4.8 cases per 100,000 person-years among users of sulfonylureas. Relevant comorbidities known as risk factors for lactic acidosis could be identified in all case subjects. A total of 2,025 case subjects with hypoglycemia and 7,278 matched control subjects were identified. Use of sulfonylureas was associated with a materially elevated risk of hypoglycemia. The adjusted odds ratio for current use of sulfonylureas was 2.79 (95% CI 2.23-3.50) compared with current metformin use.CONCLUSIONS -Lactic acidosis during current use of oral antidiabetes drugs was very rare and was associated with concurrent comorbidity. Hypoglycemic episodes were substantially more common among sulfonylurea users than among users of metformin.

Metformin Improves Neurologic Outcome Via AMP‐Activated Protein Kinase–Mediated Autophagy Activation in a Rat Model of Cardiac Arrest and Resuscitation

“…Fortunately, a nonclinical report at the 75th Scientific Sessions of the American Diabetes Association that studied the relationship between systemic metformin exposure and increased plasma lactate concentrations shows that intragastric administration of metformin (300 mg/kg) does not increase blood levels of lactic acid in normoglycemic rats 53. Two other large clinical studies have also demonstrated that there is no difference in the incidence of lactic acidosis between metformin‐ and non–metformin‐treated groups 54, 55. Herein, our data also demonstrate that the dosage of metformin used in the study is safe and does not cause hypoglycemia and lactic acidosis.…”

Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial

“…It decreases basal glucose output by suppressing gluconeogenesis and glycogenolysis in the liver and by increasing glucose uptake in muscle tissue. Because metformin does not directly stimulate insulin secretion, the risk of hypoglycemia associated with its use is lower than that associated with the use of other oral antidiabetes drugs (12). The molecular mechanism of metformin involves liver kinase B1-dependent activation of AMP-activated protein kinase (AMPK; ref.…”

Ocena częstości występowania hipoglikemii w zależności od aktywności fizycznej

“…Indeed, as evidenced by Bodmer et al, the highest risk of hypoglycaemia is present during insulin treatment (14.9%) [28]. As to the risk of oral drugs, it was 1% and 2.86%, for metformin and sulphonylureas respectively.…”